Skip to content

CaSE welcomes the BioIndustry Association as a new member

06 Dec 2016

CaSE welcomes the BioIndustry Association (BIA) into membership.

Established in 1989, the BioIndustry Association (BIA) is the UK trade association for innovative bioscience enterprises. BIA members include emerging and more established bioscience companies, pharmaceutical companies, academic research and philanthropic organisations, and service providers to the UK bioscience sector.

Their members are responsible for over ninety per cent of biotechnology-derived medicines currently in clinical development in the UK and are at the forefront of innovative scientific developments targeting areas of unmet medical need. This innovation leads to better outcomes for patients, to the development of the knowledge-based economy and to economic growth. Many of their members are small, pre-revenue companies operating at the translation interface between academia and commercialisation.

Steve Bates, CEO of the BioIndustry Association, said:
“We’re pleased to be joining CaSE to support and engage in the excellent work they do. The BIA share CaSE’s ambitions for increased public investment in science and innovation, better education and training, and greater use of evidence in policy making. These issues are essential to ensuring the UK continues to be a world-leader in the life sciences.” 

Dr Sarah Main, Executive Director of the Campaign for the Science and Engineering, said: 
“The BioIndustry Association represents the innovative heart of the UK’s world-leading biomedical sector. The BIA has been a powerful advocate for the life sciences and I am delighted to welcome such an influential organisation into our membership. I look forward to working closely with the BIA and know that their voice will reinforce ours.”

CaSE are keen to ensure the needs of the whole science and engineering community are being heard at the highest levels of government. If you are interested in finding out more about organisational membership of CaSE please contact Sharleni Inbanathan.